Legend Biotech CorporationLEGN
ASignal's systematic analysis rates LEGN as Neutral.
Reflects the latest available analysis · analyzed Aug 19, 2026
The case on LEGN
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (51.9% YoY)
- High gross margin (56.57%) indicating pricing power
- Low debt-to-equity ratio (0.23x) signaling strong financial health
- High cash reserves ($964.60M) providing operational runway
- Current ratio of 3.04x indicating strong liquidity position
- RSI at 72.16 indicating overbought conditions
- Negative MACD value (-0.84) suggesting bearish momentum
- Price below 50-day SMA (25.37) indicating downtrend
- Negative operating cash flow (-$89.40M)
- Negative return on equity (-8.08%) and return on assets (-1.92%)
See the full verdict on LEGN
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes LEGN
Most investors never get a second opinion, let alone several. ASignal runs LEGN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.